---
document_datetime: 2023-09-21 19:13:47
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrel-qualimed-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: clopidogrel-qualimed-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5817793
conversion_datetime: 2025-12-28 13:22:47.169625
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|-----------|
| IB/0008              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH product | 08/08/2011                          | n/a                                            | SmPC                             |           |
| IB/0007              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference                                                                                                         | 11/08/2010                          | n/a                                            | SmPC, Labelling and              |           |

<!-- image -->

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu Clopidogrel Qualimed Procedural steps taken and scientific information after the authorisation 1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures. 2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|           | product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                              |            |            | PL                     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IB/0005/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation | 16/06/2010 | n/a        | longer                 |
| IA/0006   | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                                                               | 01/06/2010 | n/a        |                        |
| IB/0004   | IB_18_Replacement of an excipient with a comparable excipient                                                                                                                                                                                                                                | 25/01/2010 | n/a no     | SmPC and PL            |
| II/0001   | addition of alternative manufcture for an intermediate and change in manufacturer process of intermediate Change(s) to the manufacturing process for the active substance product                                                                                                            | 17/12/2009 | 08/01/2010 |                        |
| IA/0002   | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                                                                                                                                                                      | 02/12/2009 | 02/12/2009 | SmPC, Labelling and PL |

Medicinal product no longer authorised